关于董事辞任暨选举职工代表董事的公告
Filed with SSE ·
On 6ix: 6ix.com/news/news-123
6ix hasn’t read this filing yet.
Chongqing Genrix Biopharmaceutical Co., Ltd. on 6ix
Earlier from Chongqing Genrix Biopharmaceutical
- Announcement on Resolutions of the 5th Meeting of the 2nd Board of Directors
- Announcement on Voluntary Closure of the Commercialization Cooperation for Vecantoxatug Monoclonal Antibody Injection and Silevimig Monoclonal Antibody Injection
- Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Chongqing Jurisdiction and Semi-Annual Performance Briefing
- Announcement on Voluntary Disclosure on the Acceptance of Talizumab Injection
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1803 Injection for the Treatment of Systemic Lupus Erythematosus
Later from Chongqing Genrix Biopharmaceutical
- Announcement on Voluntary Disclosure of the Inclusion of the Xeligekimab Injection in the 2025 National Medical Insurance Catalog
- Announcement on Changing Signatory Certified Public Accountant
- Announcement on Voluntary Disclosure on the Acceptance of Conditional Listing Application for GR1803 Injection
- Announcement on Voluntary Disclosure of Inclusion GR1803 Injection in the List of Priority Review Drugs
- Announcement on Resignation of Independent Director
Follow Chongqing Genrix Biopharmaceutical into a list and get an email when it puts out news.
Follow Chongqing Genrix Biopharmaceutical